◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

LAKEFRONT BIOTHERAPEUTICS (LKFT) Financial History

Name: LAKEFRONT BIOTHERAPEUTICS (LKFT) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

LAKEFRONT BIOTHERAPEUTICS (LKFT) operates in the Biotechnology industry and is headquartered in Mechelen, Belgium with about 452 employees. Its market capitalization is roughly €2 billion. In the fiscal year ended 2025-12-31, LKFT reported €1.1B in revenue and €321M in net income.

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

Interactive charts & full statements →

LKFT Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	€1.1B	€276M	€240M	€241M
Gross Profit	€1.1B	€241M	€240M	€241M
Operating Income (EBIT)	€501M	(€188M)	(€88M)	(€131M)
Net Income	€321M	€74M	€212M	(€218M)

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LKFT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	€6M	€901M	€71M	€65M	€75M	—
Gross Profit	€2M	€900M	€60M	€61M	€61M	—
Operating Income (EBIT)	(€64M)	€759M	(€42M)	(€57M)	(€159M)	—
Net Income	€14M	€782M	(€202M)	(€106M)	(€153M)	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LKFT Free Cash Flow History

LKFT Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	€3.4B	€4.1B	€4.4B	€4.7B	—
Total Liabilities	€171M	€1.2B	€1.6B	€2.2B	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LKFT viewer.

Other Companies in Biotechnology

TRAX · First Tracks Biotherapeutics, Inc. — $2 billion
BCAX · Bicara Therapeutics Inc. — $2 billion
FBRX · Forte Biosciences, Inc. — $2 billion
IDIA · Idorsia Ltd — $2 billion
LBRX · LB Pharmaceuticals Inc — $2 billion
NTLA · Intellia Therapeutics, Inc. — $2 billion
MAZE · Maze Therapeutics, Inc. — $2 billion
TYRA · Tyra Biosciences, Inc. — $2 billion

← LKFN All “L” companies LKQ →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.